Synergy Score

The selected additivity reference determines the baseline used to judge a combination. Bliss independence, Loewe additivity, and zero interaction potency are alternative reference frameworks, so the same dose-response results may be evaluated against different expectations. Researchers should therefore interpret a Synergy Score together with the model used to calculate it, rather than treating the value as reference-free.

A score summarizes treatment interaction within the experimental data used to calculate it. Because researchers examine combinations across cancer models and dose-response conditions, the result should be linked to the particular model and measurements that produced it. This context helps distinguish a promising interaction for a specific setting from a finding that may require evaluation in other cancer models.

Dose-response data provide the individual treatment activities and the observed responses produced by their combination. These measurements allow researchers to compare what the combined treatment actually achieved with the response expected under an additivity reference. The resulting comparison supports systematic evaluation across tested treatment conditions and helps identify combinations that merit further investigation.

Researchers first obtain dose-response data for the treatments individually and in combination. They then select an additivity reference, such as Bliss independence, Loewe additivity, or zero interaction potency, and compare the observed combination response with that expectation. The calculated score is interpreted as evidence of greater-than-expected activity, reduced activity, or approximate additivity.

The analysis helps identify drug pairs whose combined response appears more promising than expected from their individual activities. Researchers can use these results to compare treatment interactions across cancer models and select combinations for follow-up studies. This prioritization focuses later work on evaluating efficacy and safety rather than treating every tested pair as equally promising.

A promising score can guide follow-up studies that examine whether the combination shows useful efficacy and an acceptable safety profile. The score itself supports prioritization, but subsequent work is needed to investigate those outcomes directly. In cancer research, this links quantitative interaction analysis with deeper assessment of candidate combination therapies and their performance in relevant models.